CRTAM抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: 293T cell, Primary antibody: P00296(CRTAM Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P00296(CRTAM Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P00296(CRTAM Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

CRTAM (Class I-restricted T cell-associated molecule) is a cell surface protein belonging to the immunoglobulin superfamily, primarily expressed on activated CD8+ T cells, γδ T cells, and natural killer (NK) cells. It plays a role in immune cell interactions, particularly in mucosal and inflammatory environments. CRTAM interacts with its ligand Necl2 (nectin-like molecule 2), expressed on epithelial and dendritic cells, facilitating cell adhesion and signaling. This interaction is critical for cytotoxic T cell function, including target cell recognition and immune synapse formation.

Research highlights CRTAM's involvement in modulating immune responses, such as promoting IFN-γ secretion and enhancing cytotoxic activity. Dysregulation of CRTAM has been linked to autoimmune diseases, chronic inflammation, and cancer progression. CRTAM antibodies, either monoclonal or polyclonal, are experimental tools used to study its biological functions, block CRTAM-Necl2 interactions, or detect CRTAM expression in tissues. Recent studies explore their therapeutic potential in immune-mediated disorders, including checkpoint inhibition in cancer immunotherapy. However, the exact mechanistic pathways and clinical relevance of CRTAM-targeting antibodies remain under investigation, with ongoing efforts to clarify their role in balancing pro-inflammatory and regulatory immune signals.